Skip to main content
Erschienen in: Quality of Life Research 6/2012

01.08.2012

Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration

verfasst von: Josephine M. Norquist, Cynthia Girman, Sheri Fehnel, Carla DeMuro-Mercon, Nancy Santanello

Erschienen in: Quality of Life Research | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Understand the choice of recall period for PRO measures based on intended use, characteristics of the disease, treatment, and attributes of studies.

Methods

Current practice and considerations were reviewed within several disease areas (overactive bladder, menopausal hot flashes, niacin-induced flushing, osteoarthritis pain, irritable bowel symptoms, benign prostatic hyperplasia, and alopecia).

Results

Rationales were identified for using different recall periods, including event-driven (immediate), daily, up to weekly, and longer than weekly. This work demonstrates that (1) recall depends on what the PRO measure captures, its intended use, and attributes of the disease and study; (2) within the same disease area, recall can vary depending on the concept or phenomenon of interest; (3) recall must consider patient burden and their ability to easily and accurately recall the information requested; and (4) recall must be consistent with the duration of the trial and the scheduled clinic visits.

Conclusions

Shorter recall periods may underestimate symptom burden when symptoms have diurnal or day-to-day fluctuation and may place undue burden on patients. On the other hand, recall intervals that are too long may either over- or underestimate the health state. Therefore, appropriate criteria should be considered given attributes of the disease when selecting an adequate recall period.
Literatur
2.
Zurück zum Zitat Stull, D. E., Leidy, N. K., Parasuraman, B., & Chassany, O. (2009). Optimal recall periods for patient-reported outcomes: Challenges and potential solutions. CMRO, 24(4), 929–942. Stull, D. E., Leidy, N. K., Parasuraman, B., & Chassany, O. (2009). Optimal recall periods for patient-reported outcomes: Challenges and potential solutions. CMRO, 24(4), 929–942.
3.
Zurück zum Zitat Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., et al. (1992). The American-Urological-Association symptom index for benign prostatic hyperplasia. Journal of Urology, 148(5), 1549–1557.PubMed Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., et al. (1992). The American-Urological-Association symptom index for benign prostatic hyperplasia. Journal of Urology, 148(5), 1549–1557.PubMed
4.
Zurück zum Zitat Mularski, R. A., Rosenfeld, K., Coons, S. J., Dueck, A., Cella, D., Feuer, D., et al. (2007). Measuring outcomes in randomized prospective trials in palliative care. Journal of Pain and Symptom Management Volume, 34(1), S7–S19.CrossRef Mularski, R. A., Rosenfeld, K., Coons, S. J., Dueck, A., Cella, D., Feuer, D., et al. (2007). Measuring outcomes in randomized prospective trials in palliative care. Journal of Pain and Symptom Management Volume, 34(1), S7–S19.CrossRef
5.
Zurück zum Zitat Lipscomb, J., Gotay, C., & Snyder, C. (2007). Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA: A Cancer Journal for Clinicians, 57, 278–300.CrossRef Lipscomb, J., Gotay, C., & Snyder, C. (2007). Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA: A Cancer Journal for Clinicians, 57, 278–300.CrossRef
6.
Zurück zum Zitat National Cancer Institute. (2008). The nation’s investment in cancer research: A plan and budget proposal for fiscal year 2008. NIH Publication No. 06–6090. Available at: http://plan.cancer.gov. Accessed 22 Aug 2008. National Cancer Institute. (2008). The nation’s investment in cancer research: A plan and budget proposal for fiscal year 2008. NIH Publication No. 06–6090. Available at: http://​plan.​cancer.​gov. Accessed 22 Aug 2008.
7.
Zurück zum Zitat Brown, J. S., McNaughton, K. S., Wyman, J. F., Burgio, K. L., Harkaway, R., Bergner, D., et al. (2003). Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology, 61(4), 802–809.PubMedCrossRef Brown, J. S., McNaughton, K. S., Wyman, J. F., Burgio, K. L., Harkaway, R., Bergner, D., et al. (2003). Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology, 61(4), 802–809.PubMedCrossRef
8.
Zurück zum Zitat Williams, R. E., Kalilani, L., DiBenedetti, D. B., Zhou, X., Granger, A. L., Fehnel, S. E., et al. (2008). Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric, 11(1), 32–43.PubMedCrossRef Williams, R. E., Kalilani, L., DiBenedetti, D. B., Zhou, X., Granger, A. L., Fehnel, S. E., et al. (2008). Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric, 11(1), 32–43.PubMedCrossRef
9.
Zurück zum Zitat Carpenter, J. S., & Monahan, P. O. (2004). Accuracy of subjective hot flush reports compared with continuous sternal skin conductance monitoring. Obstetrics and Gynecology, 104(6), 1322–1326.PubMedCrossRef Carpenter, J. S., & Monahan, P. O. (2004). Accuracy of subjective hot flush reports compared with continuous sternal skin conductance monitoring. Obstetrics and Gynecology, 104(6), 1322–1326.PubMedCrossRef
10.
Zurück zum Zitat Coronary Drug Project Group. (1975). Clofibrate and niacin in coronary heart disease. Jama, 231(4), 360–381.CrossRef Coronary Drug Project Group. (1975). Clofibrate and niacin in coronary heart disease. Jama, 231(4), 360–381.CrossRef
11.
Zurück zum Zitat Juniper, E. F., Svensson, K., Mörk, A. C., & Ståhl, E. (2004). Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest, 125(1), 93–97.PubMedCrossRef Juniper, E. F., Svensson, K., Mörk, A. C., & Ståhl, E. (2004). Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest, 125(1), 93–97.PubMedCrossRef
12.
Zurück zum Zitat Furlong, W. B., Feeny, D., & Yandow, S. (2005). Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: A case study in measurement selection. Health and Quality of Life Outcomes, (3), 1477–7525. Furlong, W. B., Feeny, D., & Yandow, S. (2005). Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: A case study in measurement selection. Health and Quality of Life Outcomes, (3), 1477–7525.
13.
Zurück zum Zitat Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., & Stitt, L. W. (1988). Validation-study of WOMAC: A health-status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug-therapy in patients with osteo-arthritis of the hip or knee. Journal of Rheumatology, 15(12), 1833–1840.PubMed Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., & Stitt, L. W. (1988). Validation-study of WOMAC: A health-status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug-therapy in patients with osteo-arthritis of the hip or knee. Journal of Rheumatology, 15(12), 1833–1840.PubMed
14.
Zurück zum Zitat Camilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A., Dukes, G. E., et al. (2001). A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine, 161(14), 1733–1740.PubMedCrossRef Camilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A., Dukes, G. E., et al. (2001). A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine, 161(14), 1733–1740.PubMedCrossRef
15.
Zurück zum Zitat Leventer, S., Raudibaugh, K., Frissora, C., Mangel, A., Galbraith, K. B., Kucharik, R., et al. (2005). The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology, 128(4), A94. Leventer, S., Raudibaugh, K., Frissora, C., Mangel, A., Galbraith, K. B., Kucharik, R., et al. (2005). The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology, 128(4), A94.
16.
Zurück zum Zitat Nyhlin, H., Bang, C., Elsborg, L., Silvennoinen, J., Holme, I., Ruegg, P., et al. (2004). A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 39(2), 119–126.PubMedCrossRef Nyhlin, H., Bang, C., Elsborg, L., Silvennoinen, J., Holme, I., Ruegg, P., et al. (2004). A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 39(2), 119–126.PubMedCrossRef
17.
Zurück zum Zitat Miner, P., Stanton, D. B., Carter, F., Caras, S., Krause, G., & Steinborn, C. (2004). Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): Efficacy and safety in a 3 months US study. American Journal of Gastroenterology, 99(10), S277. Miner, P., Stanton, D. B., Carter, F., Caras, S., Krause, G., & Steinborn, C. (2004). Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): Efficacy and safety in a 3 months US study. American Journal of Gastroenterology, 99(10), S277.
18.
Zurück zum Zitat Fehnel, S., Johnston, J., Kurtz, C., & Mangel, A. (2006). Assessing global change and symptom severity in subjects with IBS: Qualitative item testing. American Journal of Gastroenterology, 101, S483. Fehnel, S., Johnston, J., Kurtz, C., & Mangel, A. (2006). Assessing global change and symptom severity in subjects with IBS: Qualitative item testing. American Journal of Gastroenterology, 101, S483.
19.
Zurück zum Zitat Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., et al. (2006). Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 130(5), 1538–1551.PubMedCrossRef Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., et al. (2006). Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 130(5), 1538–1551.PubMedCrossRef
20.
Zurück zum Zitat Lubeck, D. P., Prebil, L. A., Peeples, P., & Brown, J. S. (1999). A health related quality of life measure for use in patients with urge urinary incontinence: A validation study. Quality of Life Research, 8(4), 337–344.PubMedCrossRef Lubeck, D. P., Prebil, L. A., Peeples, P., & Brown, J. S. (1999). A health related quality of life measure for use in patients with urge urinary incontinence: A validation study. Quality of Life Research, 8(4), 337–344.PubMedCrossRef
21.
Zurück zum Zitat Reese, P. R., Pleil, A. M., Okano, G. J., & Kelleher, C. J. (2003). Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Quality of Life Research, 12(4), 427–442.PubMedCrossRef Reese, P. R., Pleil, A. M., Okano, G. J., & Kelleher, C. J. (2003). Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Quality of Life Research, 12(4), 427–442.PubMedCrossRef
22.
Zurück zum Zitat Feinstein, R. P. (2007). Androgenetic Alopecia. EMedicine (from WebMD). Feinstein, R. P. (2007). Androgenetic Alopecia. EMedicine (from WebMD).
23.
Zurück zum Zitat Olsen, E. A. (2001). Female pattern hair loss: Clinical features and potential hormonal factors. Journal of the American Academy of Dermatology, 45(3), S69.CrossRef Olsen, E. A. (2001). Female pattern hair loss: Clinical features and potential hormonal factors. Journal of the American Academy of Dermatology, 45(3), S69.CrossRef
24.
Zurück zum Zitat Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., et al. (2004). A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 50(4), 541–553.PubMedCrossRef Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., et al. (2004). A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 50(4), 541–553.PubMedCrossRef
25.
Zurück zum Zitat Revicki, D. A., Camilleri, M., Kuo, B., Norton, J. N., Murray, L., Palsgrove, A., & Parkman, H. P. (2009). Development and content validity of a gastroparesis cardinal symptom index daily diary. Alimentary Pharmacology & Therapeutics, 30(6), 670–680. Revicki, D. A., Camilleri, M., Kuo, B., Norton, J. N., Murray, L., Palsgrove, A., & Parkman, H. P. (2009). Development and content validity of a gastroparesis cardinal symptom index daily diary. Alimentary Pharmacology & Therapeutics, 30(6), 670–680.
26.
Zurück zum Zitat Revicki, D. A., Margolis, M. K., Bush, E. N., DeRogatis, L. R., & Hanes, V. (2011). Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. Journal of Sexual Medicine (Epub ahead of print). Revicki, D. A., Margolis, M. K., Bush, E. N., DeRogatis, L. R., & Hanes, V. (2011). Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. Journal of Sexual Medicine (Epub ahead of print).
Metadaten
Titel
Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration
verfasst von
Josephine M. Norquist
Cynthia Girman
Sheri Fehnel
Carla DeMuro-Mercon
Nancy Santanello
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 6/2012
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-0003-8

Weitere Artikel der Ausgabe 6/2012

Quality of Life Research 6/2012 Zur Ausgabe